Scoop: After hep B setback, an OrbiMed-backed NASH biotech hunts for partners as it raises Series C
Almost four and a half years after uncloaking a €40 million Series B, a small French biotech hopes to secure another round of financing to bankroll an FXR agonist in a subset of a field viewed as a “graveyard of products and companies,” the CEO told Endpoints News.
The OrbiMed- and Sofinnova-backed drug developer eyes a €30 million Series C by the end of this year to help launch a mid-stage trial in a portion of patients with nonalcoholic fatty liver disease, or NASH, who also have chronic kidney disease, and run a Phase II study in the rare disease Alport syndrome, a genetic condition that leads to progressive loss of kidney function.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.